Assessing EGFR-mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy.

Wei-Chun ChenWen-Chien ChengChieh-Lung ChenWei-Chih LiaoChia-Hung ChenHung-Jen ChenChih-Yen TuChi-Chen LinTe-Chun Hsia

Published in: Cancer medicine (2024)

The presence of BoM is a negative prognostic factor for NSCLC patients with an EGFR mutation, possibly due to the presence of extrathoracic metastases. However, adding AAT and denosumab, along with sequential osimertinib, to the treatment regimen for patients with BoM can improve survival outcomes.

Keyphrases

small cell lung cancer
epidermal growth factor receptor
prognostic factors
advanced non small cell lung cancer
tyrosine kinase
bone mineral density
combination therapy
wild type